Management Team


Michael Wax, President & CEO:
He is also Chief Development Officer at TriStar Wellness Solutions, Inc.   (TWSI:OTCQB) and lead the buyout of HemCon in May, 2013.  As a founding partner in TWSI he helped design the roll-up strategy of healthcare assets which include HemCon.  

In 1996 Michael moved from Boston to Bend, Oregon and co-founded DesChutes Medical Products, Inc., where as President and CEO he guided the company from the patent formation stage, through commercial product launch and to complete divestment. During his tenure at DesChutes he successfully initiated an international distribution strategy as well as introducing OTC products to the domestic retail markets. Numerous RX products were developed and harvested. In early 2009 DesChutes was sold to Jarden Corporation (JAH:NYSE).

Michael holds a graduate degree from the University of Chicago. He has been a founding board member and Chairman of Oregon State University, Cascades Campus and sat on the strategic planning board of St. Charles Medical Center in Bend, Oregon for the past three years. He currently lives in Portland, Oregon.

Simon McCarthy, Science & Technology Fellow:
Dr. McCarthy brings over 25 years of research experience in chemistry and holds multiple worldwide patents in the chemistry and medical device field. He joined HemCon in 2001 as one of the primary founders and inventors of the underlying technology utilized in the life-saving HemCon wound care solutions. Simon was named in 2005 by the US Army as a Top Ten Invention Award recipient in 2005 for invention & development of the HemCon Chitosan Bandage. He further won the Tibbets Award in 2007 for development of the HemCon Bandage and was the finalist in Australia Eureka Awards 2012 for development of the novel co-polyurethane-siloxane Elast-Eon. Dr. McCarthy, a corporate officer, has a broad mandate in all scientific and technological matters across the company reporting directly to the President and CEO.

Stuart Sands, Chief Financial Officer & Chief Operating Officer:
Stuart brings more than 15 years of experience in finance gained both through public accounting practice and public and private industry. He joined HemCon in 2008 with the acquisition of the Irish medical device company Alltracel Pharmaceuticals Plc., and prior to his appointment to Chief Operating Officer, operated as the Chief Financial Officer.  Mr. Sands is instrumental in all corporate financial initiatives, capitalizing on maximizing asset realization, supporting the emergence from Chapter 11, and the acquisition by TWSI in May 2013. Before his tenure at HemCon, Mr. Sands worked for global enterprises Ernst and Young and Tesco plc.  Mr. Sands received his Bachelor's degree in Accounting and Finance from Dublin City University, Dublin, Ireland. He is also a Chartered Accountant (ACA).  He currently is completing a Master’s in Business Administration from Babson College.

Brian H. Clare, Vice President of Technology & Product Innovation:
Dr. Brian H. Clare brings 10 years of experience in Senior Scientific and Director-level positions across a diverse range of product applications (Medical Device, Clean Energy, Green Consumer Goods, and Industrial Polymers).  Brian has served as Principal Investigator on federally-funded research grants, and is a co-inventor on 4 issued patents and 8 peer-reviewed journals in the areas of chemistry, materials science and biologically active surfaces.  He holds a BS in Chemistry from Penn State University and a PhD in Chemistry from the University of Wisconsin.

Simon J. McCarthy, Science & Technology Fellow

Máire Ní Beilliú, Vice President of Regulatory Affairs & Quality Systems:
Dr. Máire Ní Beilliú, was at HemCon Europe, before relocating to Portland, Oregon headquarters, Dr. Ní Beilliú had held the senior management position, Director of Operations Research and Development. She joined the European company in 2007. She is responsible for the regulatory component of our medical device business, with additional responsibility for directing a highly-trained U.S.-based quality operation.  Her firsthand knowledge of the HemCon subsidiary in the Czech Republic supports the company expand its international footprint. A trained scientist, with a Ph.D. in biochemistry and invaluable experience on the European side of our operations, Maire is uniquely qualified to establish the policies HemCon requires to thrive in an increasingly regulated worldwide industry.